首页> 外文期刊>Journal of Market Access & Health Policy >Key drivers for market penetration of biosimilars in Europe
【24h】

Key drivers for market penetration of biosimilars in Europe

机译:欧洲生物仿制药市场渗透的主要驱动力

获取原文
       

摘要

Background & Objectives: Potential drivers and barriers of biosimilar uptake were mainly analysed through qualitative approaches. The study objective was to conduct a quantitative analysis and identify drivers of biosimilar uptake of all available biosimilars in the European Union (EU).Methods: A three-step process was established to identify key drivers for the uptake of biosimilars in the top 10 EU member states (MS) pharmaceutical markets (Belgium, France, Germany, Greece, Hungary, Italy, Poland, Spain, Sweden, and the UK): (1) literature review to identify incentive policies in place to enhance biosimilars adoption; (2) assessment of biosimilar market dynamics based on database analysis; (3) regression model analysis on price using the following explicative variables: incentive policies; price difference between the biosimilar and the originator product; distribution channel; generic uptake and generic price cut; pharmaceutical expenditure per capita; and market competition.Results: At the stu...
机译:背景与目的:主要通过定性方法分析生物仿制药吸收的潜在驱动因素和障碍。研究目的是进行定量分析,并确定欧盟(EU)中所有可用生物仿制药吸收生物仿制药的动因。方法:建立了一个三步过程,以确定欧盟前10大生物仿制药吸收的主要动因。成员国(MS)的药品市场(比利时,法国,德国,希腊,匈牙利,意大利,波兰,西班牙,瑞典和英国):(1)文献综述,以确定旨在提高生物仿制药采用率的激励政策; (2)基于数据库分析的生物仿制药市场动态评估; (3)使用以下解释变量对价格进行回归模型分析:激励政策;生物仿制药与原始产品之间的价格差异;分销渠道;通用吸收和通用降价;人均药品支出;和市场竞争。结果:在研究...

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号